AU2001291059A1 - Expression of genes in diabetes mellitus and insulin resistance - Google Patents

Expression of genes in diabetes mellitus and insulin resistance

Info

Publication number
AU2001291059A1
AU2001291059A1 AU2001291059A AU9105901A AU2001291059A1 AU 2001291059 A1 AU2001291059 A1 AU 2001291059A1 AU 2001291059 A AU2001291059 A AU 2001291059A AU 9105901 A AU9105901 A AU 9105901A AU 2001291059 A1 AU2001291059 A1 AU 2001291059A1
Authority
AU
Australia
Prior art keywords
genes
expression
diabetes mellitus
insulin resistance
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001291059A
Other languages
English (en)
Inventor
Alan D. Attie
Samuel T. Nadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of AU2001291059A1 publication Critical patent/AU2001291059A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001291059A 2000-09-18 2001-09-18 Expression of genes in diabetes mellitus and insulin resistance Abandoned AU2001291059A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23333900P 2000-09-18 2000-09-18
US60/233,339 2000-09-18
PCT/US2001/029096 WO2002022886A2 (fr) 2000-09-18 2001-09-18 Expression de genes dans le diabete sucre et la resistance a l'insuline

Publications (1)

Publication Number Publication Date
AU2001291059A1 true AU2001291059A1 (en) 2002-03-26

Family

ID=22876830

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001291059A Abandoned AU2001291059A1 (en) 2000-09-18 2001-09-18 Expression of genes in diabetes mellitus and insulin resistance

Country Status (3)

Country Link
US (1) US7442500B2 (fr)
AU (1) AU2001291059A1 (fr)
WO (1) WO2002022886A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098441A2 (fr) * 2001-06-07 2002-12-12 Azign Bioscience A/S Procede de traitement de troubles metaboliques au moyen de neuronatine polypeptides
CN1856708A (zh) * 2002-03-20 2006-11-01 普赖德普罗特奥米克斯公司 人糖尿病介导蛋白
US20060110384A1 (en) 2002-07-10 2006-05-25 Yuji Matsuzawa Novel proteins and use thereof
US20050054599A1 (en) * 2003-05-02 2005-03-10 Coles John G. Biosynthetic platform for cardioprotective stress response in human fetal heart tissue
US20040220125A1 (en) * 2003-05-02 2004-11-04 Coles John G. Biosynthetic platform for cardioprotective gene expression using immature heart tissue
WO2005031341A2 (fr) * 2003-09-29 2005-04-07 Pfizer Health Ab Methodes pour prevoir l'apparition d'une resistance a l'insuline
WO2005059564A1 (fr) 2003-12-11 2005-06-30 Beth Israel Deaconess Medical Center, Inc. Utilisation de la proteine rbp 4 dans le traitement de la sensibilite/resistance insulinique, du diabete , et de l'obesite
WO2006063009A2 (fr) * 2004-12-07 2006-06-15 Ohio University Diagnostic de l'hyperinsulinemie et du diabete de type ii et protection contre ceux-ci sur la base de proteines exprimees differemment dans le serum
WO2007000924A1 (fr) * 2005-06-28 2007-01-04 Osaka University Préparation pharmaceutique comprenant une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline et méthode de criblage pour la recherche d'une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline
US8316007B2 (en) * 2007-06-28 2012-11-20 Oracle International Corporation Automatically finding acronyms and synonyms in a corpus
KR101591738B1 (ko) 2007-11-13 2016-02-04 베리덱스, 엘엘씨 당뇨병의 진단 생체마커
GB0816633D0 (en) * 2008-09-12 2008-10-22 Probiox Sa Method for the prognosis and diagnosis of type II diabetes in critical persons
US20110318270A1 (en) * 2009-02-27 2011-12-29 Verva Pharmaceuticals Ltd Drug identification protocol for type 2 diabetes based on gene expression signatures

Also Published As

Publication number Publication date
US20030013093A1 (en) 2003-01-16
WO2002022886A2 (fr) 2002-03-21
US7442500B2 (en) 2008-10-28
WO2002022886A3 (fr) 2003-11-20

Similar Documents

Publication Publication Date Title
AU2001291059A1 (en) Expression of genes in diabetes mellitus and insulin resistance
IL208525A0 (en) Long acting insulin for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes
AU2001274694A1 (en) Needle covering mechanism, needle holder and hypodermic syringe
AU2002225356A1 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
AU2001285047A1 (en) Human genes and gene expression products
AU2001245619A1 (en) Human genes and gene expression products
AU2002254942A1 (en) Paracetamol solutions which are stable in storage and ready for infusion
AU5203601A (en) Platen construction and swing chair
AU2001244785A1 (en) Personal computer provided with body composition analysis, electro cardiogram and pulse measurement function
AU2001288061A1 (en) Drug resistance-associated gene and use thereof
AU2002349673A1 (en) Insulin resistance improving agents
EP1272240B8 (fr) Seringue hypodermique
AU2003300899A1 (en) Genes related to sensitivity and resistance to chemotherapeutic drug treatment
AU2121200A (en) Improvements in or relating to sphygmomanometers and other devices
AU2003272903A1 (en) Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
AU2001261774A1 (en) Retractable needle and syringe combination
WO2003102163A8 (fr) Procedes de diagnostic et de traitement du diabete et de la resistance a l'insuline
AU2001233176A1 (en) Resistance sequences and uses thereof
AU2002229113A1 (en) Glucose transport-related genes and uses thereof
AU2003243427A1 (en) Methods of diagnosing and treating diabetes and insulin resistance
AU2001248809A1 (en) Novel insulin/IGF/relaxin family polypeptides and DNAs thereof
AU2003285069A1 (en) Type 2 diabetes mellitus genes
AU2002367638A1 (en) An isolated polynucleotide associated with type ii diabetes mellitus and methods of use thereof
AU2003245343A1 (en) Sequential therapy comprising a 20(s)-camptothecin and an anthracycline
IL161294A0 (en) Differentially expressed genes associated with obesity and type 2 diabetes